Clinical Trials List
2021-11-01 - 2026-06-30
Phase III
Not yet recruiting5
Recruiting2
Terminated1
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure.
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Ching-Shan Luo Division of Thoracic Medicine
- Po-Hao Feng Division of General Internal Medicine
- YUN-KAI YEH Division of Thoracic Medicine
- JING-QUAN ZHENG Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Shang-Yin Wu Division of Hematology & Oncology
- Xin-Min Liao Division of General Internal Medicine
- Jui-Hung Tsai Division of Hematology & Oncology
- Seu-Chun Yang Division of General Internal Medicine
- Wu-Chou Su Division of Hematology & Oncology
- Chun-Hui Lee Division of Hematology & Oncology
- Yau-Lin Tseng Division of Thoracic Surgery
- Yu-Min Yeh Division of Hematology & Oncology
- Po-Lan Su Division of General Internal Medicine
- Yi-Ting Yen Division of Thoracic Surgery
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Ying-Ming Tsai Tsai Division of Thoracic Medicine
- Inn-Wen Chong Division of Thoracic Medicine
- KUAN-LI WU Division of Thoracic Medicine
- Chih-Jen Yang Division of Thoracic Medicine
- 郭家佑 Division of Thoracic Medicine
- 李玫萱 Division of Thoracic Medicine
- 莊政皓 Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- KUO-HSUAN HSU Division of Thoracic Medicine
- JENG-SEN TSENG Division of Thoracic Medicine
- YEN-HSIANG HUANG Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 施穎銘 Division of Thoracic Medicine
- 詹博強 Division of Thoracic Medicine
- 林慶雄 Division of Thoracic Medicine
- 紀炳銓 Division of Thoracic Medicine
- 林明泰 Division of Thoracic Medicine
- 陳正雄 Division of Thoracic Medicine
- 林俊維 Division of Thoracic Medicine
- 張竣期 Division of Thoracic Medicine
- 葉金水 Division of Thoracic Medicine
- 黃國揚 Division of Thoracic Medicine
- 蔡偉宏 Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 徐偉勛 Division of Hematology & Oncology
- 陳冠宇 Division of General Internal Medicine
- 蔡子修 Division of General Internal Medicine
- Jih-Hsiang Lee Division of Hematology & Oncology
- James Chih-Hsin Yang Division of Hematology & Oncology
- 錢穎群 Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
- 楊景堯 Division of General Internal Medicine
- YEN-TING LIN Division of General Internal Medicine
- Chia-Chi Lin Division of Hematology & Oncology
- 黃俊凱 Division of Hematology & Oncology
- 廖唯昱 Division of General Internal Medicine
- 吳尚俊 Division of General Internal Medicine
- 廖斌志 Division of Hematology & Oncology
- Chong-Jen Yu Division of General Internal Medicine
- 許嘉林 Division of General Internal Medicine
- 林昭文 Division of Ophthalmology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 莊政皓 Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
JNJ-73841937 (Lazertinib)
Dosage Form
Tablet
Dosage
JNJ-73841937 (Lazertinib) 240 mg
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
690 participants
